Article
Oncology
Qianhui Gu, Jing Li, Zhuolin Chen, Jie Zhang, Hui Shen, Xiaobing Miao, Ying Zhou, Xiaohong Xu, Song He
Summary: Recent studies have shown that PD-L2 expression is associated with clinicopathological features in DLBCL patients. Higher expression of PD-L2 is correlated with better prognosis and survival outcomes, indicating its potential as a therapeutic target in DLBCL.
FRONTIERS IN ONCOLOGY
(2021)
Article
Oncology
Zhongqi Li, Fang Yu, Wenle Ye, Liping Mao, Jiansong Huang, Yang Shao, Junrong Yan, Wenjuan Yu, Jie Jin, Jinghan Wang
Summary: NOTCH1 mutations in DLBCL patients are associated with poor prognosis and can serve as an independent predictor.
FRONTIERS IN ONCOLOGY
(2021)
Article
Oncology
Zanzan Wang, Jiawei Zhang, Shuna Luo, Xiaoying Zhao
Summary: The study evaluated the role of systemic immune-inflammation index (SII) in predicting survival for patients with diffuse large B cell lymphoma (DLBCL). SII was found to be a powerful prognostic tool, with higher SII values indicating poorer prognosis and potentially aiding in identifying high-risk patients among those with the same international prognostic index (IPI).
FRONTIERS IN ONCOLOGY
(2021)
Article
Immunology
Shidai Mu, Deyao Shi, Lisha Ai, Fengjuan Fan, Fei Peng, Chunyan Sun, Yu Hu
Summary: The study revealed that the IPI-IPM has independent prognostic significance for DLBCL patients, showing that high-risk patients had worse overall survival and were correlated with immune-related signaling pathways, high mutation rates, and upregulation of inhibitory immune checkpoints, suggesting a greater potential response to ICB therapy.
FRONTIERS IN IMMUNOLOGY
(2021)
Review
Dentistry, Oral Surgery & Medicine
Carla Isabelly Rodrigues-Fernandes, Lucas Guimaraes Abreu, Raghu Radhakrishnan, Danyel Elias da Cruz Perez, Gleyson Kleber Amaral-Silva, Rogerio de Oliveira Gondak, Siavash Rahimi, Peter A. Brennan, Felipe Paiva Fonseca, Pablo Agustin Vargas
Summary: The expression of CD30 in DLBCL is associated with clinicopathological features and patients' survival, showing a higher survival rate and better prognosis regardless of the cut-off values used to determine CD30 positivity.
JOURNAL OF ORAL PATHOLOGY & MEDICINE
(2021)
Article
Oncology
Yan Qin, Tian Qiu, Zucheng Xie, Xinrui Chen, Peng Liu, Jianliang Yang, Xiaohui He, Lin Gui, Shengyu Zhou, Hongxin Jiang, Changgong Zhang, Sheng Yang, Le Tang, Yuankai Shi
Summary: This study investigates the clinical and molecular differences between DLBCL patients with MYD88(L265P) and MYD88(other). The results show that MYD88(L265P) is more common in the non-GCB subtype and associated with testicle/ CNS involvement, PIM1 mutation, and high mutation frequency. On the other hand, MYD88(other) is more likely to have advanced stage, multiple extranodal sites, elevated LDH, and other genetic alterations. In the non-GCB subtype, MYD88(other) is associated with worse progression-free survival when treated with R-CHOP-like regimen.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
(2023)
Article
Hematology
Shu-Yun Ma, Xiao-Peng Tian, Jun Cai, Ning Su, Yu Fang, Yu-Chen Zhang, Jin-Ni Wang, Robert Peter Gale, Qing-Qing Cai
Summary: A prognostic score for DLBCL patients based on infiltrating immune cells was constructed, showing that the immune risk score is an accurate and independent survival predictor in DLBCL patients.
BRITISH JOURNAL OF HAEMATOLOGY
(2021)
Article
Surgery
Zhuoya Zhou, Jing Chen
Summary: This study is the largest population-based study to date on independent prognostic factors of CCSV-DLBCL. Age, race, surgical resection, radiation, and chemotherapy are closely associated with patients' survival outcomes.
ASIAN JOURNAL OF SURGERY
(2023)
Article
Oncology
Wenqi Wu, Jinhuan Wang, Yanan Jiang, Xin Hu, Ye Tian, Long Chen, Huimeng Sun, Yuhang Li, Su Liu, Yangyang Lv, Jing Guo, Hong Xu, Donghui Xing, Yixin Zhai, Linyan Tian, Cheng Li, Xiang He, Kaiping Luo, Yuan Pan, Zhigang Zhao
Summary: This study constructed a prognostic model for diffuse large B-cell lymphoma (DLBCL) patients using ribosome-related genes (RibGs) and validated its predictive capability. The upregulated pathways in the high-risk group were found to be associated with innate immune reaction, and the high-risk patients were more sensitive to certain drugs. Knocking out NLE1 was also found to inhibit the proliferation of DLBCL cell lines.
Article
Oncology
Eugene Kim, Yanwen Jiang, Tao Xu, Alexandra Bazeos, Andrea Knapp, Christopher R. Bolen, Kathryn Humphrey, Tina G. Nielsen, Elicia Penuel, Joseph N. Paulson
Summary: This study applied non-negative matrix factorization (NMF) and targeted sequencing data to analyze DLBCL, and found that different mutation clusters are associated with clinical prognosis. Specifically, improved overall survival was observed in the BCL2/EZH2 group, which received venetoclax therapy.
Review
Biochemistry & Molecular Biology
Xiao-jie Liang, Xin-yu Song, Jia-lin Wu, Dan Liu, Bing-yu Lin, Hong-sheng Zhou, Liang Wang
Summary: This article provides an overview of the research advances in DLBCL prognostic biomarkers using a multi-omics approach. It emphasizes the urgent need for highly specific and sensitive biomarkers to predict the therapeutic response of DLBCL and assess patient benefit from systemic chemotherapy. The use of systems biology in DLBCL research is highlighted for its comprehensive quantification and identification of biomarkers and its potential to address major biological problems with high accuracy and sensitivity.
INTERNATIONAL JOURNAL OF BIOLOGICAL SCIENCES
(2022)
Article
Endocrinology & Metabolism
Jiaqin Yan, Wei Yuan, Junhui Zhang, Ling Li, Lei Zhang, Xudong Zhang, Mingzhi Zhang
Summary: In this study, we established a prognostic prediction model with eight genes that can effectively predict the survival outcomes of DLBCL patients. We also created a nomogram to visualize the prediction model and explored immune alterations between high- and low-risk groups.
FRONTIERS IN ENDOCRINOLOGY
(2022)
Review
Oncology
Mei Lin, Shupei Ma, Lingling Sun, Zhiqiang Qin
Summary: This study analyzed the prognostic implications of tumor-associated macrophages (TAMs) in the microenvironment of diffuse large B cell lymphoma (DLBCL). The results showed that a high density of M2 TAMs was significantly associated with advanced disease stage and unfavorable overall survival in DLBCL patients.
FRONTIERS IN ONCOLOGY
(2023)
Review
Oncology
Dan Cao, Zongxin Zhang
Summary: This meta-analysis found that a lower level of geriatric nutritional risk index (GNRI) is associated with poorer prognosis in patients with diffuse large B-cell lymphoma (DLBCL), as well as clinical factors of disease progression.
FRONTIERS IN ONCOLOGY
(2023)
Article
Biotechnology & Applied Microbiology
Yi-an Zhang, Xue Yang, Jiamei Yao, Yuhong Ren, Peng Liu
Summary: This study found that the expression of CXCR4 in diffuse large B-cell lymphoma is associated with worse prognosis, suggesting it as a potential therapeutic target.
Article
Oncology
Xiaoli Sun, Yu Jia, Yuanyu Wei, Shuai Liu, Baohong Yue
MOLECULAR MEDICINE REPORTS
(2016)
Article
Oncology
Xiaoli Sun, Yu Jia, Yuanyu Wei, Shuai Liu, Baohong Yue
Article
Multidisciplinary Sciences
Jia Li, Ningning Wang, Nahom Tesfaluul, Xiaojuan Gao, Shuai Liu, Baohong Yue
Article
Hematology
Ningning Wang, Nahom Tesfaluul, Jia Li, Xiaojuan Gao, Shuai Liu, Baohong Yue
ANNALS OF HEMATOLOGY
(2019)
Article
Medical Laboratory Technology
Yaqi Wang, Yu Jia, Chunyan Wang, Xiaojuan Gao, Yuke Liu, Baohong Yue
JOURNAL OF CLINICAL LABORATORY ANALYSIS
(2020)
Article
Immunology
Qiyao Pu, Xueyan Cao, Yuke Liu, Dongyao Yan, Ran Tan, Jiwei Li, Baohong Yue
Summary: This study comprehensively analyzed the immunophenotype of mature NK cell tumors using flow cytometry, showing distinct expression patterns among different disease groups. This provides important references for the diagnosis and prognosis of tumors.
FRONTIERS IN IMMUNOLOGY
(2022)